An atypical case of SCN9A mutation presenting with global motor delay and a severe pain disorder

Muscle Nerve. 2014 Jan;49(1):134-8. doi: 10.1002/mus.23968. Epub 2013 Nov 22.

Abstract

Introduction: Erythromelalgia due to heterozygous gain-of-function SCN9A mutations usually presents as a pure sensory-autonomic disorder characterized by recurrent episodes of burning pain and redness of the extremities.

Methods: We describe a patient with an unusual phenotypic presentation of gross motor delay, childhood-onset erythromelalgia, extreme visceral pain episodes, hypesthesia, and self-mutilation. The investigation of the patient's motor delay included various biochemical analyses, a comparative genomic hybridization array (CGH), electromyogram (EMG), and muscle biopsy. Once erythromelalgia was suspected clinically, the SCN9A gene was sequenced.

Results: The EMG, CGH, and biochemical tests were negative. The biopsy showed an axonal neuropathy and neurogenic atrophy. Sequencing of SCN9A revealed a heterozygous missense mutation in exon 7; p.I234T.

Conclusions: This is a case of global motor delay and erythromelalgia associated with SCN9A. The motor delay may be attributed to the extreme pain episodes or to a developmental perturbation of proprioceptive inputs.

Keywords: Nav1.7; SCN9A; axonal neuropathy; developmental delay; erythromelalgia; pain.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Carbamazepine / therapeutic use
  • Child, Preschool
  • Comorbidity
  • Erythromelalgia / drug therapy
  • Erythromelalgia / epidemiology
  • Erythromelalgia / genetics
  • Female
  • Humans
  • Hypesthesia / drug therapy
  • Hypesthesia / epidemiology
  • Hypesthesia / genetics
  • Mexiletine / therapeutic use
  • Motor Skills Disorders / drug therapy
  • Motor Skills Disorders / epidemiology
  • Motor Skills Disorders / genetics*
  • Mutation, Missense / genetics*
  • NAV1.7 Voltage-Gated Sodium Channel / genetics*
  • Severity of Illness Index*
  • Somatoform Disorders / drug therapy
  • Somatoform Disorders / epidemiology
  • Somatoform Disorders / genetics*
  • Treatment Outcome

Substances

  • NAV1.7 Voltage-Gated Sodium Channel
  • SCN9A protein, human
  • Mexiletine
  • Carbamazepine